Detalhe da pesquisa
1.
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Mol Cancer
; 23(1): 115, 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38811992
2.
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Oncologist
; 29(5): e690-e698, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377176
3.
Mesothelioma: Pleural, Version 1.2024.
J Natl Compr Canc Netw
; 22(2): 72-81, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38503043
4.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591293
5.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469185
6.
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(11)2023 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37298380
7.
Neoadjuvant or Perioperative Approach in Lung Cancer.
N Engl J Med
; 390(19): 1816-1818, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38749039
8.
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Future Oncol
; 18(23): 2593-2604, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35722877
9.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 22(10): 1438-1447, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499874
10.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285097
11.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658856
12.
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy.
Cancer Immunol Immunother
; 70(9): 2429-2438, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33797567
13.
Thymoma and thymic carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.
Pediatr Blood Cancer
; 68 Suppl 4: e29042, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881200
14.
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Future Oncol
; 17(10): 1165-1184, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33583206
15.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035514
16.
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Lancet Oncol
; 21(7): 914-922, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32539942
17.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914866
18.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959700
19.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Acta Oncol
; 59(9): 1058-1063, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32762415
20.
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Curr Oncol Rep
; 22(5): 41, 2020 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32296957